These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 27419209)
21. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes. Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H; J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116 [TBL] [Abstract][Full Text] [Related]
22. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study. Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906 [TBL] [Abstract][Full Text] [Related]
23. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW; Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850 [TBL] [Abstract][Full Text] [Related]
26. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H Diabetes Res Clin Pract; 2015 Jun; 108(3):441-7. PubMed ID: 25795273 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. Sato S; Saisho Y; Kou K; Meguro S; Tanaka M; Irie J; Kawai T; Itoh H PLoS One; 2015; 10(3):e0121988. PubMed ID: 25816296 [TBL] [Abstract][Full Text] [Related]
28. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes. da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958 [TBL] [Abstract][Full Text] [Related]
29. A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment. Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H Intern Med; 2015; 54(23):2981-9. PubMed ID: 26631880 [TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500 [TBL] [Abstract][Full Text] [Related]
32. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K; Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683 [TBL] [Abstract][Full Text] [Related]
34. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. Kutoh E J Med Case Rep; 2011 Mar; 5():117. PubMed ID: 21443773 [TBL] [Abstract][Full Text] [Related]
35. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881 [TBL] [Abstract][Full Text] [Related]
37. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Jalaludin MY; Deeb A; Zeitler P; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD; Shankar RR Pediatr Diabetes; 2022 Mar; 23(2):183-193. PubMed ID: 34779103 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726 [TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin. Shibuki K; Shimada S; Aoyama T Diabetes Metab Syndr; 2022 Apr; 16(4):102474. PubMed ID: 35378386 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]